AI tumor board review for kidney cancer
Kidney cancer runs from small masses found on scans done for other reasons to metastatic disease, and the board’s questions change across that range: whether to treat at all, how to treat the kidney, and what systemic therapy adds.
Kidney cancer reviews are available now.
Read the sample report, from a prostate cancer case.
Request accessWhere the specialties split
Where the specialties at a kidney cancer tumor board split
- Small renal mass management
- For a small renal mass, active surveillance, thermal ablation and partial nephrectomy are all options. The board weighs the tumor’s size and growth, what a biopsy shows, kidney function and the patient’s overall health.
- Adjuvant therapy after nephrectomy
- After surgery for clear cell renal cell carcinoma at higher risk of recurrence, adjuvant immunotherapy can lower that risk. Medical oncology and urology weigh the benefit against the side effects for each patient.
- First-line metastatic RCC
- In metastatic renal cell carcinoma (RCC), the first-line choice is usually among immunotherapy-based combinations. The board also weighs whether removing the kidney, or treating individual metastases with surgery or radiation, has a role.
Who sits at the board
Who sits at a kidney cancer tumor board
- Urology
- Partial or radical nephrectomy, and surveillance of small masses.
- Medical oncology
- Adjuvant and systemic therapy.
- Radiology
- How a mass looks on imaging, and, in interventional radiology, biopsy and thermal ablation.
- Pathology
- Subtype and grade, which shape both the risk of recurrence and the choice of systemic therapy.
- Radiation oncology
- Stereotactic radiation for selected tumors and metastases.
More GU cancers
Request access for your practice
Prostate, bladder and kidney cancer reviews are available now. We read every request and will get back to you within two business days.
Request access